Jpmorgan Chase & CO Standard Biotools Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LAB
# of Institutions
149Shares Held
264MCall Options Held
422KPut Options Held
40.7K-
Casdin Capital, LLC New York, NY64MShares$136 Million9.76% of portfolio
-
Viking Global Investors LP58.7MShares$124 Million0.41% of portfolio
-
Black Rock Inc. New York, NY21.8MShares$46.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16MShares$33.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY12.9MShares$27.4 Million0.0% of portfolio
About STANDARD BIOTOOLS INC.
- Ticker LAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 78,654,800
- Market Cap $167M
- Description
- Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar ...